FDA product evidence mapped to briefs, portfolios, and indication-target networks.
Practical perspectives on FDA product evidence, labeling changes, indication context, and the workflows teams use to turn public regulatory sources into strategic signal.
A research brief on therapeutic aging science, with emphasis on OSK partial reprogramming, first-in-human development, and the broader translational gap between longevity biology and approvable medical products.
A research brief on therapeutic aging science, with emphasis on OSK partial reprogramming, first-in-human development, and the broader translational gap between longevity biology and approvable medical products.
Read articleIL-6 in 2026 is no longer a single-brand category. The market is defined by a crowded tocilizumab franchise, narrower approved positions for sarilumab, satralizumab, and siltuximab, and a late-stage pipeline that is pushing the pathway into new neurologic and cardiometabolic settings.
Read articleHow adalimumab, infliximab, etanercept, certolizumab pegol, and golimumab now differ on biosimilar depth, route strategy, regional status, and commercial posture.
Read articleHow the IL-17 class now divides between mature IL-17A incumbents, a fast-scaling IL-17A/F challenger, and a narrower next wave of pipeline assets.
Read articleSelective IL-23-pathway therapies now span skin, joints, bowel disease, biosimilar-exposed legacy products, and the first oral IL-23 receptor antagonist, creating a more segmented and strategically important market than the earlier psoriasis-only class.
Read article